From these findings, the combined blocking of TNF-α and IL-17A may represent a new option for controlling inflammatory bone disorders as in RA, psoriatic arthritis as well as in ankylosing spondylitis and inflammatory subsets of OA and even common osteoporosis. This evidence concerns the gene TNF and ankylosing spondylitis.